The specific contribution of NK cell-mediated ADCC on the clinical benefit of anti-HER2 mAb in breast cancer patients could be modulated by several NK cell-, tumor cell- and therapy-related variables (Figure 2). Here, ERBB2 is linked to breast cancer.